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1.1 General introduction
The definition of anaesthesia has been changing ever since it was first publicly demonstrated 
in 1846. The main reason for this is that our exact understanding of comprehensive mechanism 
of action of “anaesthetic drugs” remains limited despite a vast body of knowledge of action on 
the cellular and molecular level.1
Currently, The American Society of Anesthesiologists defines anaesthesia as a “reversible drug 
induced state in which patients are not arousable, not even by painful stimuli”.2 It is commonly 
accepted that this drug induced state comprises different traits which can be divided in two 
different components, namely: 
 - The hypnotic component which encompasses lack of conscious processing and memory. 
 - The analgesic component which encompasses lack of movement and lack of autonomic 
    response to noxious stimulation which includes but is not limited to hemodynamic   
    stability. 
Each trait can be induced by multiple drugs and each drug can induce a spectrum of different 
effects. The “hypnotics” such as benzodiazepines3, barbiturates and volatile anesthetics4 
predominantly cause unconsciousness and lack of pain perception (nociception) by modifying 
the function of cortical and subcortical structures but in high enough doses can also induce 
physical and physiological unresponsiveness5. Opiate and non-opiate analgesic drugs 
predominantly ensure lack of responsiveness by blocking the transmission of noxious and non-
noxious environmental stimuli from the peripheral nervous system to subcortical and cortical 
structures6 but also cause a hypnotic sparing effect through synergy with the hypnotics (see 
figure 1). The muscle relaxants cause physical unresponsiveness by blocking the neuromuscular 
transmission while leaving consciousness and perception of environmental stimuli intact. 
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Figure 1. Image reproduced from “Handbook of experimental pharmacology.”6
The titration of these drugs to optimal clinical eff ect is very important. When they are 
administered in excessive doses these drugs can cause serious cardio-pulmonary side eff ects 
and might, in view of some (controversial) evidence, even compromise the long term outcome7 8. 
Underdosing on the other hand can lead to equally serious consequences such as awareness9 10,
hemodynamic instability and unexpected patient movement. Furthermore with an aging 
population11 and the greater demands for more complex surgical procedures, the need for fi ne-
tuned anaesthetic management is greater than ever. Therefore it is important to optimize drug 
administration by maximizing the clinical eff ect while minimizing the unwanted (side) eff ects. 
In practice anaesthetists have multiple resources at their disposal to optimize drug titration. This 
introduction will describe, in brief, these resources and their relation to this thesis. In chapter 2 
these subjects will be covered more extensively.   
1.2 Means to optimize titration of drugs 
Adequate knowledge of anaesthetic pharmacology is fundamental for rational drug dosing. To 
quote the words of professor Struys: “Everything starts with education”12. 
Pharmacology comprises pharmacokinetics and pharmacodynamics. Pharmacokinetics (PK) 
is a science which relates administered drug dose to measured drug concentration while 
pharmacodynamics (PD) relates the measured drug concentration to drug eff ect.13 An anaesthetic 
drug dose-response relation can therefore be divided in three diff erent parts; the relation between 
the administered drug dose and the blood plasma concentration (pharmacokinetic part), the 
relation between the concentration and the clinical (side) eff ect and interaction between the 
pharmacokinetic and pharmacodynamics14 (fi gure 2).  
509881-L-bw-sahinovic
Processed on: 1-5-2017 PDF page: 11
11  
Figure 2. Adapted from Absalom et al.13 Graphs generated using PkPd tools15 for Excel.  
Graph shows Pk and Pd calculated using the Schnider mode 16 with Keo of 0.456 for an 18 year old male, weight 70 
kg, height 160 cm after a 150 mg bolus of  propofol administered during the fi rst 30 seconds.  
1.2.1 Pharmacokinetics 
The physiological and chemical processes which govern drug pharmacokinetics have still not 
entirely been elucidated. Nonetheless, several empirical mathematical models give us insight into 
the non-linear relation between drug dose and concentration in diff erent parts of the body. These 
(in anaesthesiology) generally multi-compartment models can be either classical16–19 (abstract) or 
physiologically based20. Each kind has its pros and cons.  
Varied methods of pharmacokinetic modelling have been used in the past.21 Currently the most 
widely used and accepted method is population based mixed eff ects analysis.22 This method is often 
used with a proprietary computer package “NONMEM” (nonlinear mixed eff ects modelling)23 24.
The main diff erence between mixed eff ects modelling and more traditional methods of modelling 
is that the former method not only models the fi xed eff ects, such as age, weight and gender, in a 
structural and covariate model but also models random eff ects such as intra- and interindividual 
variability in a statistical model. As a result mixed eff ects analysis can limit the infl uence of 
outlying samples and individuals, use data generated by less stringent study designs and can 
handle uneven amounts of data from diff erent subjects. This makes it a very robust method of 
pharmacokinetic modelling.  
Propofol is the most commonly administered intravenous drug in anaesthetic practice. A number 
of pharmacokinetic models for propofol exist.16 17 18 All were developed and evaluated using 
1. General introduction and outline of the thesis
509881-L-bw-sahinovic
Processed on: 1-5-2017 PDF page: 12
pharmacokinetic data from patients without brain tumours. Nevertheless they are often used 
during TCI propofol anaesthesia for patients with brain tumours. Because of patho-physiological 
changes associated with the presence and treatment of a brain tumour, their use in anaesthesia 
for neurosurgery might not be entirely appropriate. This was our incentive to investigate the 
pharmacokinetics of propofol in these patients more extensively using mixed effects modelling 
in chapter 4.
1.2.2 Pharmacodynamics 
Measuring the achieved drug effect is an integral part of any rational drug dosing scheme. Ideally 
we should measure the drug concentration (and effect) at the site of its action, i.e. at the receptor 
level. However this is currently not possible. Therefore we depend on monitoring of (secondary) 
clinical effects of the drugs in order to assess if an optimal drug state is reached.  
1.3 EEG derived drug effect monitors, the basics 
Research and development of the EEG based drug effect monitors has been underway ever 
since Gibbs and Gibbs first described systematic drug induced changes in the EEG in 1937. Two 
different types of EEG activity can be monitored. These are 1) spontaneously generated cortical 
electrical activity and 2) stimulus (motor or sensory) evoked cortical activity, also known as evoked 
potential activity.25 In contrast to spontaneously generated EEG which merely reflects the activity 
of superficial layers of the cortex, monitoring the evoked potentials also provides information 
about the function of afferent/efferent neural pathways and deeper structures of the brain.   
After acquisition, amplification, digitalisation and artefact rejection, the EEG signal can be 
processed. Two main methods of signal processing are widely accepted.26 The first is analysis 
in time domain, in other words the analysis of the amplitude (μ V) of the EEG signal in time. 
Parameters which can be calculated this way include certain types of entropy (a measure of 
disorder within the signal), a burst suppression (BS) and burst suppression rate (BSR) quantification 
or in other words quantification of time when the signal shows an isoelectric pattern interspersed 
with burst of activity. The second method of analysis is analysis in the frequency domain. For this 
analysis EEG is deconstructed into its component frequencies using fast Fourier transformation 
thereby producing a power spectrum of the EEG.27 Frequencies can be arbitrarily divided into 
frequency bands ranging from slow frequencies (0-4 Hz, delta band) to fast frequencies (>30 Hz, 
gamma band). The most noted parameters which can be calculated from this analysis are the 
peak frequency (frequency with the highest power), median frequency (frequency dividing the 
power spectrum in two), spectral edge frequency (frequency below which 95% of the EEG power 
is situated) and the bispectrum (analysis of the inter-frequency phase relationship between 
different frequencies).28
1.3.1 Monitoring the hypnotic cortical drug effect  
Current hypnotic drug effect monitors rely on changes in processed electroencephalogram 
(pEEG) in order to quantify the cortical drug effect.29 30 Many different monitors are commercially 
available. Although the Narcotrend index and the State and Response Entropy (SE and RE) are also 
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very established in the clinical practice, the BIS (Bispectral Index) monitor is worldwide the most 
widely used during anaesthesia for neurosurgery for quantifying hypnotic drug effect. Although 
all of these monitors have been extensively investigated and validated in clinical practice, no 
studies have specifically addressed the issue of the influence of frontal brain tumours on the 
relationship between the monitor output and the conscious state.  Therefore in chapter 3 we set 
out to investigate this relationship in patients with frontal brain tumours for a Bispectral index 
monitor. 
1.3.2 Monitoring the analgesic cortical drug effect 
In contrast to the hypnotic drug effect monitors, no real cortical drug effect monitors exist for 
the analgesics. Ever since it was demonstrated, in the 1990’s, by different research groups that 
the anaesthetic ability to suppress the responses to the noxious stimuli is independent of cortical 
structures,31 32 the research on the analgesic effect monitoring has focused mainly on subcortical 
effect monitors. Only after the relatively recently published results demonstrating that noxious 
stimulation and analgesic drug administration cause significant changes to the cerebral function, 
which are amendable to measurement,33 34 has the interest in developing a cortical analgesic 
drug effect monitor been rekindled. 
Multiple analgesia monitors which infer the (in)adequacy of analgesia by assessing the changes 
in autonomic nervous system outflow in response to noxious stimulation have been proposed. 
Surgical Pleth Index (SPI), pupillometry and Analgesia Nociception Index (ANI ) are a few examples.35 
But, because these monitors rely, in order to quantify (an)algesia, on secondary variables which 
are susceptible to influence by non-noxious/analgesic stimuli, their accuracy is inherently limited. 
Recently it has been demonstrated that cortical arousal generated by inadequately blocked 
noxious stimulation can be measured. Ellerkmann and colleagues showed that perturbation in 
cortical activity caused by ascending inadequately blocked “noxious” stimuli cause an increase 
in BIS and facial EMG variability. These changes have been condensed into a single index, the 
Composite Variability Index (CVI). Ellerkmann has already investigated the index performance in 
detection of noxious stimulation, however he did not account for the influence of hypnotic drugs 
on the performance of CVI. Therefore in chapter 5 we attempt to investigate the accuracy of CVI 
under wide range of analgesic and hypnotic drugs. 
1.3.3 Monitoring the combination of hypnotic and analgesic cortical drug effects 
Composite Input (CI) and Composite State (CS) are novel parameters developed by Shoustarian 
and colleagues.36 They constructed, using neurophysiological knowledge behind rhythmogenesis 
of the human EEG, a mathematical model of the effects of hypnotic and analgesic drugs on the 
human EEG. Using the approximation of this model they developed two indices, CI and CS. CI 
quantifies the magnitude of input into cortex from sub-cortical structures and can be -in theory- 
influenced by analgesic drugs while CS reflects the current state of the cortex and is mainly the 
representation of the hypnotic anti-hypnotic balance.  
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The performance of these hypnotic and analgesic measures individually has already been 
extensively investigated. However, their combined performance has never been assessed. 
Because clear and synergistic interactions between hypnotic and analgesic drugs have been 
described in literature it stands to reason that combined and simultaneous monitoring of hypnotic 
and analgesic components of anaesthesia might offer better insight into combined drug dose 
effect. That was the main motivation to set up the study described in chapter 6. In that study 
we investigated individual and combined performance of these kindred hypnotic and analgesic 
monitors, BIS-CVI and CI-CS, to detect nociceptic events and predict patient movement.  
In summary, in this thesis we aimed to investigate: 
 - In chapter 2 the literature behind the rational drug dosing and drug effect monitoring.  
 - In chapter 3 two commonly held perceptions among anaesthetists i.e.  
  - Patients with brain tumours are more susceptible to hypnotic effects of propofol.
  - Frontal brain tumour influences output of BIS-monitor thus rendering it unreliable   
    for drug dose titration. 
 - In chapter 4 whether the pathophysiological changes associated with a frontal brain tumour 
   influences the pharmacokinetics of propofol in patients undergoing craniotomy.  
 - In chapter 5 the efficiency of the Composite Variability Index to quantify the nociception
   anti-nociception balance.  
 - In chapter 6 whether combining the established and the newly developed hypnotic and 
   nociception-anti nociception measures CVI/BIS and CI/CS respectively could improve our
   ability to optimize both hypnotic and analgesic drug dosing in order to prevent movement
   secondary to noxious and non-noxious stimulation.  
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